Stone GW,Witzenbichler B, Guagliumi G, et al. Bivalirudin during prima- ry PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218 30. 249. R ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angio- graphic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitax- el-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011;123:2819 28. 250. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive net- work meta-analysis. Lancet. 2012;379:1393 402. 251. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J. 2009;30:900 7. 252. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987;76:125 34. 253. Mehta SR, Bassand J-P, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930 42. Erratum in: N Engl J Med. 2010;363:1585. 254. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71 86. Erratum in: BMJ. 2002;324:141. 255. Sch mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary- artery stents. N Engl J Med. 1996;334:1084 9. 256. Deleted in press. 257. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foun- dation. Circulation. 2011;124: 2458 73. 258. Patti G, B rczi G, Orlic D, et al. 